Genmab’s epcoritamab succeeds in frontline DLBCL

Also: Alvotech’s FDA capacity win, CSL–Alentis deal worth up to $1.6bn, new Idorsia data at AHA.

Genmab’s epcoritamab succeeds in frontline DLBCL Beitrag lesen »